Ivermectin and Doxycycline combination as a promising anti-viral drug candidate: an in-silico and DFT study

伊维菌素和多西环素联合用药作为一种有前景的抗病毒候选药物:计算机模拟和密度泛函理论研究

阅读:1

Abstract

In contemporary area of medical research, repurposing of drugs has emerged as a promising strategy in drug discovery against viral infections in individual or in combination modes. The 3-chymotrypsin-like protease (3CL(pro)) plays an essential role in mediating viral replication in the human body. It is key for developing potent and selective inhibitors for inhibiting viral replication. In this work, we have studied the possible efficacy of two popularly used repurposed drugs: Ivermectin and Doxycycline in their individual and combination modes as anti-viral agents. Density functional theory (DFT) was used to establish the chemical reactivity of the proposed drugs. Molecular electrostatic potential (MEP) and charge distribution analysis were used to check the antiviral effectivity. The study included the characteristics of the drug: 3CL(pro) interactions through in-silico molecular docking and molecular dynamic (MD) simulation approaches through various thermodynamic parameters (E(pot), T, V, D, R(g), SASA energy) for identifying better reactiveness of both Ivermectin and Doxycycline in their individual and combination modes. Individually, Ivermectin showed a good binding affinity (-6.9 kcal/mol) over Doxycycline (-6.4 kcal/mol). In combination mode, Ivermectin + Doxycycline has showed a significant enhancement in the binding affinity (-7.4 kcal/mol). Our Insilco output has established that both individual and combination modes of prescribed repurposed drugs: Ivermectin and Doxycycline can be used as antiviral target towards the infections caused by 3CL(pro) protease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。